| |
SAPS-SLE (n=7) |
aPL+ SLE (n=4) |
Vascular PAPS (n=40) |
Obstetric PAPS (n=22) |
| Female, n (%) |
5 (71%) |
2 (50%) |
27 (68%) |
22 (100%) |
| Thrombosis |
6 (85%) |
/ |
40/40 (100%) |
/ |
| Obstetric manifestations |
2 (29%) |
/ |
7 (17.5%) |
22 (100%) |
| Positive LA |
5 (72%) |
2 (50%) |
29 (73%) |
18 (82%) |
| aCL IgG, GPL (median, IQR) |
14 (12-106.5) |
58 (27.5-91.25) |
82 (46-103) |
41 (5-75) |
| aCL IgM, MPL (median, IQR) |
7 (3-8.5) |
4 (0.75-7.25) |
7 (2-16) |
8 (2-17) |
| Anti-β2GPI IgG, OD (median, IQR) |
0.67 (0.335-1.125) |
0.985 (0.76-1.13) |
1.24 (0.37-1.55) |
0.49 (0.115-1.162) |
| Anti-β2GPI IgM, OD (median, IQR) |
0.23 (0.17-0.43) |
0.16 (0.095-1.2675) |
0.25 (0.1-0.89) |
0.13 (0.082-0.217) |
| Anti-D1, OD (median, IQR) |
0.7 (0.4-2) |
0.980 (0.373-1.541) |
0.409 (0.212-0.74) |
0.267 (0.191-0.493) |
| Anti-D4/5, OD (median, IQR) |
0.25 (0.13-0.20) |
0.226 (0.167-0.267) |
0.233 (0.148-0.342) |
0.151 (0.134-0.226) |
|
